AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data by Seini Moimoi | Nov 8, 2019 | Portfolio News
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants by Seini Moimoi | Nov 7, 2019 | Portfolio News
Talaris Therapeutics Presents Data Supporting Potential of FCR001 to Prevent Recurrence of Kidney-Related Autoimmune Disease in Kidney Transplant Recipients by Seini Moimoi | Nov 7, 2019 | Portfolio News
Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer by Seini Moimoi | Nov 7, 2019 | Portfolio News
